Literature DB >> 30339629

Genetic Analysis of Small Well-differentiated Pancreatic Neuroendocrine Tumors Identifies Subgroups With Differing Risks of Liver Metastases.

Antonio Pea1,2, Jun Yu1, Luigi Marchionni3, Michael Noe4, Claudio Luchini4,5, Alessandra Pulvirenti2, Roeland F de Wilde4, Lodewijk A Brosens6, Neda Rezaee1, Ammar Javed1, Peter Chianchiano4, Stefano Gobbo7, Paolo Regi8, Roberto Salvia2, Claudio Bassi2, Jin He1, Matthew J Weiss1, John L Cameron1, G Johan A Offerhaus6, Ralph H Hruban4, Rita T Lawlor9, Aldo Scarpa5,9, Christopher M Heaphy4, Laura D Wood4, Christopher L Wolfgang1.   

Abstract

OBJECTIVE: The aim of this study was to investigate the key molecular alterations in small primary pancreatic neuroendocrine tumors (PanNETs) associated with the development of liver metastases.
BACKGROUND: Well-differentiated PanNETs with small size are typically indolent; however, a limited subset metastasize to the liver.
METHODS: A total of 87 small primary PanNETs (<3 cm), including 32 metastatic cases and 55 nonmetastatic cases after a 5-year follow-up, were immunolabeled for DAXX/ATRX and analyzed for alternative lengthening of telomeres (ALT) by Fluorescence In Situ Hybridization. A subset of these cases, 24 that metastasized and 24 that did not metastasize, were assessed by targeted next-generation sequencing and whole-genome copy number variation.
RESULTS: In the entire cohort, high Ki-67 (OR 1.369; 95% CI 1.121-1.673; P = 0.002), N-stage (OR 4.568; 95% CI 1.458-14.312; P = 0.009), and ALT-positivity (OR 3.486; 95% CI 1.093-11.115; P = 0.035) were independently associated with liver metastases. In the subset assessed by next-generation sequencing and copy number variation analysis, 3 molecular subtypes with differing risks of liver metastases were identified. Group 1 (n = 15; 73% metastasized) was characterized by recurrent chromosomal gains, CN-LOH, DAXX mutations, and ALT-positivity. Group 2 (n = 19; 42% metastasized, including 5 G1 tumors) was characterized by limited copy number alterations and mutations. Group 3 (n = 14; 35% metastasized) were defined by chromosome 11 loss.
CONCLUSIONS: We identified genomic patterns of small PanNETs associated with a different risk for liver metastases. Molecular alterations, such as DAXX mutations, chromosomal gains, and ALT, are associated with an increased risk of metastasis in small PanNETs. Therefore, targeted sequencing and/or ALT analysis may help in the clinical decisions for these small PanNETs.

Entities:  

Mesh:

Year:  2020        PMID: 30339629      PMCID: PMC6565500          DOI: 10.1097/SLA.0000000000003022

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   13.787


  35 in total

Review 1.  mTOR signaling in growth control and disease.

Authors:  Mathieu Laplante; David M Sabatini
Journal:  Cell       Date:  2012-04-13       Impact factor: 41.582

2.  Whole-genome landscape of pancreatic neuroendocrine tumours.

Authors:  Aldo Scarpa; David K Chang; Katia Nones; Vincenzo Corbo; Ann-Marie Patch; Peter Bailey; Rita T Lawlor; Amber L Johns; David K Miller; Andrea Mafficini; Borislav Rusev; Maria Scardoni; Davide Antonello; Stefano Barbi; Katarzyna O Sikora; Sara Cingarlini; Caterina Vicentini; Skye McKay; Michael C J Quinn; Timothy J C Bruxner; Angelika N Christ; Ivon Harliwong; Senel Idrisoglu; Suzanne McLean; Craig Nourse; Ehsan Nourbakhsh; Peter J Wilson; Matthew J Anderson; J Lynn Fink; Felicity Newell; Nick Waddell; Oliver Holmes; Stephen H Kazakoff; Conrad Leonard; Scott Wood; Qinying Xu; Shivashankar Hiriyur Nagaraj; Eliana Amato; Irene Dalai; Samantha Bersani; Ivana Cataldo; Angelo P Dei Tos; Paola Capelli; Maria Vittoria Davì; Luca Landoni; Anna Malpaga; Marco Miotto; Vicki L J Whitehall; Barbara A Leggett; Janelle L Harris; Jonathan Harris; Marc D Jones; Jeremy Humphris; Lorraine A Chantrill; Venessa Chin; Adnan M Nagrial; Marina Pajic; Christopher J Scarlett; Andreia Pinho; Ilse Rooman; Christopher Toon; Jianmin Wu; Mark Pinese; Mark Cowley; Andrew Barbour; Amanda Mawson; Emily S Humphrey; Emily K Colvin; Angela Chou; Jessica A Lovell; Nigel B Jamieson; Fraser Duthie; Marie-Claude Gingras; William E Fisher; Rebecca A Dagg; Loretta M S Lau; Michael Lee; Hilda A Pickett; Roger R Reddel; Jaswinder S Samra; James G Kench; Neil D Merrett; Krishna Epari; Nam Q Nguyen; Nikolajs Zeps; Massimo Falconi; Michele Simbolo; Giovanni Butturini; George Van Buren; Stefano Partelli; Matteo Fassan; Kum Kum Khanna; Anthony J Gill; David A Wheeler; Richard A Gibbs; Elizabeth A Musgrove; Claudio Bassi; Giampaolo Tortora; Paolo Pederzoli; John V Pearson; Nicola Waddell; Andrew V Biankin; Sean M Grimmond
Journal:  Nature       Date:  2017-02-15       Impact factor: 49.962

3.  Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors.

Authors:  Aatur D Singhi; Ta-Chiang Liu; Justin L Roncaioli; Dengfeng Cao; Herbert J Zeh; Amer H Zureikat; Allan Tsung; J Wallis Marsh; Kenneth K Lee; Melissa E Hogg; Nathan Bahary; Randall E Brand; Kevin M McGrath; Adam Slivka; Kristi L Cressman; Kimberly Fuhrer; Roderick J O'Sullivan
Journal:  Clin Cancer Res       Date:  2016-07-12       Impact factor: 12.531

4.  Altered telomeres in tumors with ATRX and DAXX mutations.

Authors:  Christopher M Heaphy; Roeland F de Wilde; Yuchen Jiao; Alison P Klein; Barish H Edil; Chanjuan Shi; Chetan Bettegowda; Fausto J Rodriguez; Charles G Eberhart; Sachidanand Hebbar; G Johan Offerhaus; Roger McLendon; B Ahmed Rasheed; Yiping He; Hai Yan; Darell D Bigner; Sueli Mieko Oba-Shinjo; Suely Kazue Nagahashi Marie; Gregory J Riggins; Kenneth W Kinzler; Bert Vogelstein; Ralph H Hruban; Anirban Maitra; Nickolas Papadopoulos; Alan K Meeker
Journal:  Science       Date:  2011-06-30       Impact factor: 47.728

5.  Population-level analysis of pancreatic neuroendocrine tumors 2 cm or less in size.

Authors:  Eric J Kuo; Ronald R Salem
Journal:  Ann Surg Oncol       Date:  2013-06-15       Impact factor: 5.344

6.  Cytological differentiation of asymptomatic pancreatic islet cell tumours in autopsy material.

Authors:  L Grimelius; G T Hultquist; B Stenkvist
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1975

7.  Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway.

Authors:  Edoardo Missiaglia; Irene Dalai; Stefano Barbi; Stefania Beghelli; Massimo Falconi; Marco della Peruta; Lorenzo Piemonti; Gabriele Capurso; Alessia Di Florio; Gianfranco delle Fave; Paolo Pederzoli; Carlo M Croce; Aldo Scarpa
Journal:  J Clin Oncol       Date:  2009-11-16       Impact factor: 44.544

8.  Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors.

Authors:  Roeland F de Wilde; Christopher M Heaphy; Anirban Maitra; Alan K Meeker; Barish H Edil; Christopher L Wolfgang; Trevor A Ellison; Richard D Schulick; I Quintus Molenaar; Gerlof D Valk; Menno R Vriens; Inne H M Borel Rinkes; G Johan A Offerhaus; Ralph H Hruban; Karen E Matsukuma
Journal:  Mod Pathol       Date:  2012-05-11       Impact factor: 7.842

9.  Adjustment of genomic waves in signal intensities from whole-genome SNP genotyping platforms.

Authors:  Sharon J Diskin; Mingyao Li; Cuiping Hou; Shuzhang Yang; Joseph Glessner; Hakon Hakonarson; Maja Bucan; John M Maris; Kai Wang
Journal:  Nucleic Acids Res       Date:  2008-09-10       Impact factor: 16.971

10.  CTLPScanner: a web server for chromothripsis-like pattern detection.

Authors:  Jian Yang; Jixiang Liu; Liang Ouyang; Yi Chen; Bo Liu; Haoyang Cai
Journal:  Nucleic Acids Res       Date:  2016-05-16       Impact factor: 16.971

View more
  20 in total

Review 1.  Clinical applications of (epi)genetics in gastroenteropancreatic neuroendocrine neoplasms: Moving towards liquid biopsies.

Authors:  Gitta Boons; Timon Vandamme; Marc Peeters; Guy Van Camp; Ken Op de Beeck
Journal:  Rev Endocr Metab Disord       Date:  2019-09       Impact factor: 6.514

2.  Histologic and molecular features of small well-differentiated pancreatic neuroendocrine tumors associated with the development of liver metastases.

Authors:  Paula Jiménez-Fonseca; Patricia Morales Del Burgo; Felipe Alvarez-Manceñido
Journal:  Hepatobiliary Surg Nutr       Date:  2019-08       Impact factor: 7.293

3.  Infiltration pattern predicts metastasis and progression better than the T-stage and grade in pancreatic neuroendocrine tumors: a proposal for a novel infiltration-based morphologic grading.

Authors:  Orhun Cig Taskin; Michelle D Reid; Pelin Bagci; Serdar Balci; Ayse Armutlu; Deniz Demirtas; Burcin Pehlivanoglu; Burcu Saka; Bahar Memis; Emine Bozkurtlar; Can Berk Leblebici; Adelina Birceanu; Yue Xue; Mert Erkan; Yersu Kapran; Arzu Baygul; Cenk Sokmensuer; Aldo Scarpa; Claudio Luchini; Olca Basturk; Volkan Adsay
Journal:  Mod Pathol       Date:  2021-12-30       Impact factor: 7.842

Review 4.  Prognostic factors for the outcome of nonfunctioning pancreatic neuroendocrine tumors in MEN1: a systematic review of literature.

Authors:  S M Sadowski; C R C Pieterman; N D Perrier; F Triponez; G D Valk
Journal:  Endocr Relat Cancer       Date:  2020-06       Impact factor: 5.678

5.  The genomic landscape of 85 advanced neuroendocrine neoplasms reveals subtype-heterogeneity and potential therapeutic targets.

Authors:  Job van Riet; Harmen J G van de Werken; Edwin Cuppen; Ferry A L M Eskens; Margot Tesselaar; Linde M van Veenendaal; Heinz-Josef Klümpen; Marcus W Dercksen; Gerlof D Valk; Martijn P Lolkema; Stefan Sleijfer; Bianca Mostert
Journal:  Nat Commun       Date:  2021-07-29       Impact factor: 14.919

6.  Gene Expression Profiling of Pancreas Neuroendocrine Tumors with Different Ki67-Based Grades.

Authors:  Michele Simbolo; Mirna Bilotta; Andrea Mafficini; Claudio Luchini; Daniela Furlan; Frediano Inzani; Gianluigi Petrone; Davide Bonvissuto; Stefano La Rosa; Giovanni Schinzari; Antonio Bianchi; Ernesto Rossi; Roberta Menghi; Felice Giuliante; Stefania Boccia; Aldo Scarpa; Guido Rindi
Journal:  Cancers (Basel)       Date:  2021-04-23       Impact factor: 6.639

7.  Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium.

Authors:  Michael Goggins; Kasper Alexander Overbeek; Randall Brand; Sapna Syngal; Marco Del Chiaro; Detlef K Bartsch; Claudio Bassi; Alfredo Carrato; James Farrell; Elliot K Fishman; Paul Fockens; Thomas M Gress; Jeanin E van Hooft; R H Hruban; Fay Kastrinos; Allison Klein; Anne Marie Lennon; Aimee Lucas; Walter Park; Anil Rustgi; Diane Simeone; Elena Stoffel; Hans F A Vasen; Djuna L Cahen; Marcia Irene Canto; Marco Bruno
Journal:  Gut       Date:  2019-10-31       Impact factor: 23.059

Review 8.  Alternative Lengthening of Telomeres (ALT) in Pancreatic Neuroendocrine Tumors: Ready for Prime-Time in Clinical Practice?

Authors:  Claudio Luchini; Rita T Lawlor; Samantha Bersani; Caterina Vicentini; Gaetano Paolino; Paola Mattiolo; Antonio Pea; Sara Cingarlini; Michele Milella; Aldo Scarpa
Journal:  Curr Oncol Rep       Date:  2021-07-16       Impact factor: 5.075

9.  Quantitative Computed Tomography Image Analysis to Predict Pancreatic Neuroendocrine Tumor Grade.

Authors:  Alessandra Pulvirenti; Rikiya Yamashita; Jayasree Chakraborty; Natally Horvat; Kenneth Seier; Caitlin A McIntyre; Sharon A Lawrence; Abhishek Midya; Maura A Koszalka; Mithat Gonen; David S Klimstra; Diane L Reidy; Peter J Allen; Richard K G Do; Amber L Simpson
Journal:  JCO Clin Cancer Inform       Date:  2021-06

10.  Platinum-Based Treatment for Well- and Poorly Differentiated Pancreatic Neuroendocrine Neoplasms.

Authors:  Alessandra Pulvirenti; Nitya Raj; Sara Cingarlini; Antonio Pea; Laura H Tang; Claudio Luchini; Joanne F Chou; Elisabetta Grego; Ioana Marinova; Marinela Capanu; Luca Landoni; Aldo Scarpa; Peter J Allen; David S Klimstra; Diane L Reidy-Lagunes
Journal:  Pancreas       Date:  2021-02-01       Impact factor: 3.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.